XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals Ltd. - American Depositary Shares (XTLB)
US:NASDAQ Investor Relations:
xtlbio.com
Company Research
Source: GlobeNewswire
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) today announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), a biotechnology company pioneering disease-modifying therapeutics targeting the core pathophysiology of Autism Spectrum Disorder (ASD) and neuro-o
Show less
Read more
Impact Snapshot
Event Time:
XTLB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XTLB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XTLB alerts
High impacting XTL Biopharmaceuticals Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
XTLB
News
- XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice [Seeking Alpha]Seeking Alpha
- XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency [Yahoo! Finance]Yahoo! Finance
- XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyGlobeNewswire
XTLB
Sec Filings
- 1/13/26 - Form 6-K
- 12/30/25 - Form 6-K
- 12/29/25 - Form 6-K
- XTLB's page on the SEC website